BioCentury | Apr 4, 2016
Clinical News

Diclofenac: Clinical trial data

...from baseline to days 3, 5 and 8 vs. placebo (p=0.0018, p=0.0416 and p=0.049, respectively). Nuvo...
...U.S., where it is approved to treat pain due to osteoarthritis (OA) of the knee. Nuvo Pharmaceuticals Inc....
BioCentury | Mar 14, 2016
Company News

Crescita, Nuvo Pharma drug delivery, inflammation, neurology news

...formerly Nuvo Research Inc. ) spun out its drug development business into stand-alone company Crescita. Nuvo...
...postherpetic neuralgia. Crescita has rights to develop and market Pliaglis lidocaine/tetracaine in North America from Nuvo...
...in cash. Horizon Pharma plc (NASDAQ:HZNP, Dublin, Ireland) has U.S. rights to Pennsaid 2% from Nuvo...
BioCentury | Jan 4, 2016
Clinical News

WF10: Development discontinued

...ragweed allergy seasons and then in the EEC after the end of the ragweed season. Nuvo...
BioCentury | Sep 21, 2015
Company News

Nuvo drug delivery, inflammation, neurology news

...it plans to spin out its drug development business into a stand-alone, publicly traded company. Nuvo...
...profitable commercial company focused on its Pennsaid diclofenac franchise. The spinout would focus on developing Nuvo’s...
...chlorite matrix is in Phase II testing to treat allergic rhinitis. If approved by shareholders, Nuvo...
BioCentury | Jun 15, 2015
Company News

Horizon Pharma, Perrigo deal

...Horizon said there were no financial terms. Horizon purchased U.S. rights to Pennsaid 2% from Nuvo...
BioCentury | May 4, 2015
Clinical News

WF10: Phase II start

...This month, Nuvo will begin the double-blind, placebo-controlled, Canadian Phase II 2015 WF10 Trial to evaluate...
...ragweed allergy seasons and then in the EEC after the end of the ragweed season. Nuvo...
BioCentury | Feb 9, 2015
Clinical News

WF10: Phase II data

...WF10, WF10 with chlorate and sulphate removed, WF10 with chlorite and sulphate removed or placebo. Nuvo...
...“demonstrated a much greater than anticipated reduction in allergy symptom scores.” WF10 was well tolerated. Nuvo...
...a review of the data and expects to report additional data “in the coming weeks.” Nuvo...
BioCentury | Dec 8, 2014
Company News

Nuvo, Horizon Pharma deal

...Horizon purchased from Nuvo U.S. rights to Pennsaid 2% diclofenac for $45 million in cash. Pennsaid...
...osteoarthritis (OA) of the knee. Horizon plans to launch the product in early next month. Nuvo...
BioCentury | Oct 6, 2014
Company News

Nuvo, Covidien deal

...Mallinckrodt will return to Nuvo U.S. rights to Pennsaid diclofenac and Pennsaid 2% and pay Nuvo...
...last year, had U.S. rights to Pennsaid from Nuvo under a 2009 deal. Last year, Nuvo...
...said Nuvo's complaint was without merit (see BioCentury, June 22, 2009 & Nov. 11, 2013). Nuvo...
BioCentury | Sep 15, 2014
Clinical News

WF10: Completed Phase II enrollment

...a double-blind, placebo-controlled, German Phase II trial evaluating IV WF10 once daily for 5 days. Nuvo...
Items per page:
1 - 10 of 362
BioCentury | Apr 4, 2016
Clinical News

Diclofenac: Clinical trial data

...from baseline to days 3, 5 and 8 vs. placebo (p=0.0018, p=0.0416 and p=0.049, respectively). Nuvo...
...U.S., where it is approved to treat pain due to osteoarthritis (OA) of the knee. Nuvo Pharmaceuticals Inc....
BioCentury | Mar 14, 2016
Company News

Crescita, Nuvo Pharma drug delivery, inflammation, neurology news

...formerly Nuvo Research Inc. ) spun out its drug development business into stand-alone company Crescita. Nuvo...
...postherpetic neuralgia. Crescita has rights to develop and market Pliaglis lidocaine/tetracaine in North America from Nuvo...
...in cash. Horizon Pharma plc (NASDAQ:HZNP, Dublin, Ireland) has U.S. rights to Pennsaid 2% from Nuvo...
BioCentury | Jan 4, 2016
Clinical News

WF10: Development discontinued

...ragweed allergy seasons and then in the EEC after the end of the ragweed season. Nuvo...
BioCentury | Sep 21, 2015
Company News

Nuvo drug delivery, inflammation, neurology news

...it plans to spin out its drug development business into a stand-alone, publicly traded company. Nuvo...
...profitable commercial company focused on its Pennsaid diclofenac franchise. The spinout would focus on developing Nuvo’s...
...chlorite matrix is in Phase II testing to treat allergic rhinitis. If approved by shareholders, Nuvo...
BioCentury | Jun 15, 2015
Company News

Horizon Pharma, Perrigo deal

...Horizon said there were no financial terms. Horizon purchased U.S. rights to Pennsaid 2% from Nuvo...
BioCentury | May 4, 2015
Clinical News

WF10: Phase II start

...This month, Nuvo will begin the double-blind, placebo-controlled, Canadian Phase II 2015 WF10 Trial to evaluate...
...ragweed allergy seasons and then in the EEC after the end of the ragweed season. Nuvo...
BioCentury | Feb 9, 2015
Clinical News

WF10: Phase II data

...WF10, WF10 with chlorate and sulphate removed, WF10 with chlorite and sulphate removed or placebo. Nuvo...
...“demonstrated a much greater than anticipated reduction in allergy symptom scores.” WF10 was well tolerated. Nuvo...
...a review of the data and expects to report additional data “in the coming weeks.” Nuvo...
BioCentury | Dec 8, 2014
Company News

Nuvo, Horizon Pharma deal

...Horizon purchased from Nuvo U.S. rights to Pennsaid 2% diclofenac for $45 million in cash. Pennsaid...
...osteoarthritis (OA) of the knee. Horizon plans to launch the product in early next month. Nuvo...
BioCentury | Oct 6, 2014
Company News

Nuvo, Covidien deal

...Mallinckrodt will return to Nuvo U.S. rights to Pennsaid diclofenac and Pennsaid 2% and pay Nuvo...
...last year, had U.S. rights to Pennsaid from Nuvo under a 2009 deal. Last year, Nuvo...
...said Nuvo's complaint was without merit (see BioCentury, June 22, 2009 & Nov. 11, 2013). Nuvo...
BioCentury | Sep 15, 2014
Clinical News

WF10: Completed Phase II enrollment

...a double-blind, placebo-controlled, German Phase II trial evaluating IV WF10 once daily for 5 days. Nuvo...
Items per page:
1 - 10 of 362